Colorectal Cancer Cohort Study (COLO-COHORT)
Research type
Research Study
Full title
Colorectal Cancer Cohort Study (COLO-COHORT)
IRAS ID
259905
Contact name
Colin Rees
Contact email
Sponsor organisation
South Tyneside and Sunderland NHS Foundation Trust
Clinicaltrials.gov Identifier
Pending, ClinicalTrials.Gov
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
Bowel cancer is the second commonest cause of cancer death in the UK with 16000 people dying per year. Although the NHS Bowel Cancer Screening Programme (BCSP) detects cancers at an earlier stage only 10% of all cancers are detected through screening.
Currently, the only criteria for screening is age and no account is taken of other known risk factors such as smoking, alcohol, family history or obesity. Stool FIT (a new stool test which detects blood that can’t be seen with the naked eye) will be introduced into the English BCSP, but there is poor evidence for its use in patients presenting with symptoms. There are emerging data that there may be differences in the gut bacteria of people with and without cancer or pre cancerous bowel polyps (adenomas).
This will be a national multi-centre study over 5-years. 10000 Patients undergoing colonoscopy as part of BCSP or due to symptoms will be recruited. They will be asked to fill in a health questionnaire, have their height, weight, waist circumference measured. They will also receive blood tests, stool tests or saliva tests depending on the indication for their colonoscopy. The results of the colonoscopy and any samples taken will be collated. Patients will receive a patient experience questionnaire or food frequency questionnaire. 10000 patients from the North of England will also be consented to be contacted for future studies with some of the information above collected.
Our aim is to develop a risk model to help determine which patients are at highest risk of having adenomas or bowel cancer. We will also explore the significance of the gut bacteria composition in patients with adenomas or cancer to help inform this risk model. Additionally we will develop a large platform of patients who consent to be contacted for future research.
REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
19/WM/0193
Date of REC Opinion
20 Jun 2019
REC opinion
Favourable Opinion